Company: CDLX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0001666071-25-000034
Chunk: 117

Company: Cardlytics, Inc.
Filing Date: 2025-03-12
Form: 10-K
Item: Item 8
Chunk 117
---
Effect of exchange rates on cash, cash equivalents and restricted cash(110)118 (1,926)Net decrease in cash, cash equivalents and restricted cash(26,236)(30,155)(111,577)Cash, cash equivalents, and restricted cash — Beginning of period91,830 121,985 233,562 Cash, cash equivalents, and restricted cash — End of period$65,594 $91,830 $121,985 

See notes to the consolidated financial statements69

CARDLYTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

Year Ended December 31, 202420232022Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:Cash and cash equivalents$65,594 $91,830 $121,905 Restricted cash— — 80 Total cash, cash equivalents and restricted cash — End of period$65,594 $91,830 $121,985 Supplemental schedule of non-cash investing and financing activities:Cash paid for interest$6,119 $4,240 $2,381 Amounts accrued for property and equipment$95 $579 $67 Amounts accrued for capitalized software development costs$174 $40 $155 Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)$27,451 $— $— 

See notes to the consolidated financial statements70